Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances

Key facts

Sponsor

Vanda Pharmaceuticals

Intervention

Data collection of sleep disturbances in individuals with SMS(other)

Enrollment

1000 enrolled

Eligibility

3-65 years · All sexes

Timeline

2016 – 2030

Study locations (1)

• Vanda Pharmaceuticals, Washington D.C., District of Columbia, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Smith-Magenis syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT05116904
  Smith Magenis Syndrome and Autism Spectrum Disorders
  Hospices Civils de Lyon
• ACTIVE NOT RECRUITINGNANCT00013559
  Natural History Study of Smith-Magenis Syndrome
  National Human Genome Research Institute (NHGRI)

See all trials for Smith-Magenis syndrome →